Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: An observational study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Vashishtha, Richa ^a   Mohan, Krishna ^a   Singh, Bhagteshwar ^a   Devarapu, Satish K ^a   Sreenivas, Vishnubhatla ^a   Ranjan, Sanjay ^a   Gupta, Deepak ^a   Sinha, Sanjeev ^a   Sharma, Surendra K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antitubercular agents therapeutic use; HIV infections complications; Mortality; Treatment outcome; Tuberculosis drug therapy

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOPTYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PREDICTION; PROSPECTIVE STUDY; PRURITUS; PSYCHOSIS; RASH; SHORT COURSE THERAPY; SPUTUM SMEAR; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOSIS; VIRUS IDENTIFICATION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84885000462     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-468     Document Type: Article

References (31)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009-1021. 10.1001/archinte.163.9.1009, 12742798.
2. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool KQ. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706. 10.1056/NEJMoa0905848, 3076221, 20181971.
3. World Health Organization (WHO) Treatment of tuberculosis: Guidelines. 4th ed 2010, Geneva: WHO Press, World Health Organization (WHO).
4. De Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annual Rev Med 2004, 55:283-301.
5. Perlman DC, Leung CC, Yew WW. Treatment of tuberculosis in HIV-infected patients: we need to know more. Am J Respir Crit Care Med 2007, 175(11):1102-1103. 10.1164/rccm.200702-248ED, 17519346.
6. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America (IDSA) Treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America (IDSA).
7. Dlodlo RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals?. Eur Respir J 2005, 25:751-757. 10.1183/09031936.05.10090404, 15802352.
8. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, Chaisson RE. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999, 13:1899-1904. 10.1097/00002030-199910010-00012, 10513648.
9. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996, 154(4):1034-1038. 10.1164/ajrccm.154.4.8887603, 8887603.
10. Kassim S, Sassan-Morokro M, Ackah A, Abouya LY, Digbeu H, Yesso G, Coulibaly IM, Coulibaly D, Whitaker PJ, Doorly R, Vetter KM, Brattegaard K, Gnaore E, Greenberg AE, Wiktor SZ, De Cock KM. Two-year follow-up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995, 9(10):1185-1192. 10.1097/00002030-199510000-00011, 8519456.
11. Nahid P, Gonzalez LC, Rudoy I. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007, 175(11):1199-1206. 10.1164/rccm.200509-1529OC, 1899273, 17290042.
12. Swaminathan S, Narendran G, Venkatesan P, Illiayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: randomized clinical trial. Am J Respir Crit Care Med 2010, 181:743-751. 10.1164/rccm.200903-0439OC, 19965813.
13. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995, 332:779-784. 10.1056/NEJM199503233321204, 7862181.
14. El Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, Jones BE, Telzak EE, Klein O, Heifets L, Hafner R. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998, 26(5):1148-1158. 10.1086/520275, 9597244.
15. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004, 364:1244-1251. 10.1016/S0140-6736(04)17141-9, 15464185.
16. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010, 50(9):1288-1299. 10.1086/651686, 20353364.
17. Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang ZH, Mugerwa RD, Ellner JJ. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2000, 4(11):1032-1040. 3419476, 11092715.
18. Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 2006, 10(1):39-44. 2869085, 16466035.
19. Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, Rubaramira R, Mugyenyi P, Okwera A, Mugerwa R. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995, 76(3):210-218. 10.1016/S0962-8479(05)80007-3, 7548903.
20. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, Sreenivas V, Kadhiravan T, Miglani S, Sinha S, Wig N, Biswas A, Vajpayee M. Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bull World Health Organ 2010, 88:222-226. 10.2471/BLT.09.068759, 2828789, 20428391.
21. Karmakar S, Sharma SK, Vashishta R, Sharma A, Ranjan S, Gupta D, Sreenivas V, Sinha S, Biswas A, Gulati V. Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol 2011, 2011:239021. 3003953, 21197457.
22. National Tuberculosis Association of the USA Diagnostic standards and classification of tuberculosis 1961, New York: National Tuberculosis Association, National Tuberculosis Association of the USA.
23. World Health Organization Laboratory services in tuberculosis control II. Microscopy 1999, Italy: WHO Press, World Health Organization.
24. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare Tuberculosis control in India 2005, New Delhi: Elsevier, Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare.
25. National AIDS Control Organisation (NACO) Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis 2007, New Delhi: NACO, National AIDS Control Organisation (NACO).
26. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997, 35:907-914. 229700, 9157152.
27. Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu. Nigeria. Niger J Med 2006, 15(3):222-226.
28. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003, 37:101-112. 10.1086/375220, 12830415.
29. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE, . CAMELIA (ANRS 1295-CIPRA KH001) Study Team Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365(16):1471-1481. 10.1056/NEJMoa1013911, 22010913, CAMELIA (ANRS 1295-CIPRA KH001) Study Team.
30. Dhingra VK, Rajpal S, Aggarwal N, Aggarwal JK, Shadab K, Jain SK. Adverse drug reactions observed during DOTS. J Commun Dis 2004, 236:251.
31. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 2001, 4:CD000970.